Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 14/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9737937 | 0.99 | SOAT1 (0.97) | SOAT1 | |
| SCHEMBL9738125 | 0.88 | SOAT1 (0.78) | SOAT1 | |
| SCHEMBL9698135 | 0.86 | SOAT1 (0.75) | SOAT1 | |
| SCHEMBL9737543 | 0.86 | SOAT1 (0.75) | SOAT1 | |
| SCHEMBL9699233 | 0.86 | SOAT1 (0.75) | SOAT1 | |
| SCHEMBL9737518 | 0.85 | SOAT1 (1.00) | SOAT1 | |
| Hydrochloric Acid SCHEMBL9737544 | 0.85 | SOAT1 (0.73) | SOAT1 | |
| Hydrochloric Acid SCHEMBL9737229 | 0.85 | SOAT1 (0.73) | SOAT1 | |
| Hydrochloric Acid SCHEMBL9737227 | 0.85 | SOAT1 (0.73) | SOAT1 | |
| SCHEMBL9738850 | 0.84 | SOAT1 (0.73) | SOAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| US-5102900-A | Antilipemic and anticholesterol agents | RHONE-POULENC RORER S.A. (FR) | 1992-04-07 | — | — | US | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| US-5102900-A | Antilipemic and anticholesterol agents | RHONE-POULENC RORER S.A. (FR) | 1992-04-07 | — | — | US | disclosed |
| EP-0424195-A1 | Imidazoles | RHONE-POULENC SANTE (FR) | 1991-04-24 | — | — | EP | disclosed |